捐赠者特异性抗体在体外膜氧化桥梁肺移植接收者中
Lydia E Federico1, Joshua M Diamond2, Malek Kamoun3
1Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Annals of thoracic surgery short reports
|January 10, 2025
概括
肺外膜氧化 (ECMO) 可能增加肺移植后新生捐赠者特异抗体 (dnDSA) 的风险,但在调整混杂因子后,这种关联没有显著意义. 限制性输血实践可能会减轻在ECMO桥接接收者中的dNDSA风险.
科学领域:
- 心脏病学 心脏病学
- 免疫学 免疫学 免疫学
- 移植 移植 移植 移植
背景情况:
- 体外膜氧化 (ECMO) 越来越多地被用作肺移植的桥梁.
- 对于ECMO引起敏感性和抗体形成的潜力,包括新的捐赠者特异性抗体 (dnDSA),仍然不清楚.
- 其他机械循环支持装置与抗人类白细胞抗原抗体的发展有关.
研究的目的:
- 调查ECMO桥梁是否与肺移植接受者中 dnDSA 发展的风险增加有关.
- 为了比较dNDSA的发生率在ECMO桥接与非ECMO暴露的肺移植接受者中.
- 评估dndsa对ECMO桥接接接收者慢性肺异位移植无功能生存的影响.
主要方法:
- 进行了一项单中心回顾性队列研究.
- 肺移植接受者被分为ECMO桥梁和非ECMO暴露组.
- 在两组之间比较了dNDSA发育和慢性肺全移植功能障碍无生存率.
主要成果:
- 在33%的ECMO桥接接收者中, dnDSA发生,而非ECMO暴露的接收者中,这一比例为21.5%.
- 在双变量分析 (HR 2.08) 中,ECMO与dNDSA相关,但在多变量分析 (HR 1.10) 中没有相关.
- 更高的移植后输血量与 dnDSA 独立相关 (HR 4.68).
- 与 dnDSA 的ECMO桥接接收者相比,与没有 dnDSA 或与 dnDSA 的非ECMO接收者相比,调整后的生存率并不差.
结论:
- 在肺移植中,ECMO桥梁可能不是 dnDSA 发生的独立风险因素.
- 限制性移植后输血门可能会降低在ECMO桥接接收者中dnDSA的风险.
- 在ECMO桥接接收者中,dnDSA监测可能主要在存在全移植功能障碍时是合理的.
相关概念视频
Bone Marrow Sampling and Transplants
279
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
279
Blood Transfusion and Agglutination
10.7K
Blood transfusion is a therapeutic measure to restore the blood volume after extensive blood loss due to an accident or a medical procedure. Blood transfusion involves drawing a certain amount of blood from a suitable donor and infusing it into the recipient.
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
10.7K


